AUB ScholarWorks

Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus

Show simple item record

dc.contributor.author Issa C.M.
dc.contributor.author Azar S.T.
dc.contributor.editor
dc.date Oct-2012
dc.date.accessioned 2017-10-05T15:41:38Z
dc.date.available 2017-10-05T15:41:38Z
dc.date.issued 2012
dc.identifier 10.1007/s11892-012-0291-6
dc.identifier.isbn
dc.identifier.issn 15344827
dc.identifier.uri http://hdl.handle.net/10938/18113
dc.description.abstract Unfortunately, the only approved medical treatment for type 1 diabetesmellitus (DM) is insulin, despite the fact that tight control cannot be reached without some serious side effects such as hypoglycemia and weight gain.More and more importance is now shifted towards developing new drugs that can reach a better glycemic control with lesser side effects. Some of these promising drugs are the glucagon-like peptides 1 (GLP-1) and their agonists, which have been FDA approved for the treatment of type 2 DM. The purpose of this article is to review all of the relevant literature on the potential role of GLP-1 in the treatment of type 1 DM. Themajor source of data acquisition includedMedline search strategies, using the words type 1 diabetes mellitus and GLP-1. Articles published in the last 20 years were screened. GLP-1 increases insulin secretion in humans with existing beta cells; it also decreases glucagon secretion, and blunts appetite. Of note, new animal studies demonstrate a role in beta cell-proliferation and decreased apoptosis. Because of all the effects mentioned above, GLP-1 seems to be a promising drug for type 1 DM treatment, but more studies are still needed before solid conclusions can be drawn. © Springer Science+Business Media, LLC 2012.
dc.format.extent
dc.format.extent Pages: (560-567)
dc.language English
dc.publisher PHILADELPHIA
dc.relation.ispartof Publication Name: Current Diabetes Reports; Publication Year: 2012; Volume: 12; no. 5; Pages: (560-567);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus
dc.type Article
dc.contributor.affiliation Issa, C.M., Department of Internal Medicine, Division of Endocrinology and Metabolism, American University of Beirut-Medical Center, 3 Dag Hammarskjold Plaza, 8th floor, New York, NY 10017, United States
dc.contributor.affiliation Azar, S.T., Department of Internal Medicine, Division of Endocrinology and Metabolism, American University of Beirut-Medical Center, 3 Dag Hammarskjold Plaza, 8th floor, New York, NY 10017, United States
dc.contributor.authorAddress Azar, S.T.; Department of Internal Medicine, Division of Endocrinology and Metabolism, American University of Beirut-Medical Center, 3 Dag Hammarskjold Plaza, 8th floor, New York, NY 10017, United States; email: sazar@aub.edu.lb
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine; Division: Endocrinology;
dc.contributor.authorDepartment Internal Medicine
dc.contributor.authorDivision Endocrinology
dc.contributor.authorEmail sazar@aub.edu.lb
dc.contributor.faculty Faculty of Medicine
dc.contributor.authorInitials Issa, CM
dc.contributor.authorInitials Azar, ST
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Azar, ST (reprint author), Amer Univ Beirut, Dept Internal Med, Div Endocrinol and Metab, Med Ctr, 3 Dag Hammarskjold Plaza,8th Floor, New York, NY 10017 USA.
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Anderson MS, 2005, ANNU REV IMMUNOL, V23, P447, DOI 10.1146-annurev.immunol.23.021704.115643; Baggio LL, 2007, GASTROENTEROLOGY, V132, P2131, DOI 10.1053-j.gastro.2007.03.054; Balks HJ, 1997, J CLIN ENDOCR METAB, V82, P786, DOI 10.1210-jc.82.3.786; Bayliss WM, 1902, J PHYSIOL-LONDON, V28, P235; Behme MT, 2003, BMC ENDOCR DISORD, V10, P1; BELL GI, 1983, NATURE, V304, P368, DOI 10.1038-304368a0; BROWN JC, 1971, CAN J BIOCHEM CELL B, V49, P255; BROWN JC, 1971, CAN J BIOCHEM CELL B, V49, P867; BROWN JC, 1970, J PHYSIOL-LONDON, V209, P57; Brubaker PL, 2004, ENDOCRINOLOGY, V145, P2653, DOI 10.1210-en.2004-0015; Burcelin R, 2008, DIABETES METAB, V34, P627, DOI 10.1016-j.diabet.2008.08.002; Creutzfeldt WOC, 1996, DIABETES CARE, V19, P580, DOI 10.2337-diacare.19.6.580; Deacon CF, 2004, DIABETES, V53, P2181, DOI 10.2337-diabetes.53.9.2181; Devendra D, 2004, BRIT MED J, V328, P750, DOI 10.1136-bmj.328.7442.750; DINNEEN S, 1995, DIABETOLOGIA, V38, P337, DOI 10.1007-BF00400639; Drucker DJ, 1999, AM J PHYSIOL-GASTR L, V276, pG79; Drucker DJ, 1996, P NATL ACAD SCI USA, V93, P7911, DOI 10.1073-pnas.93.15.7911; DUMOULIN V, 1995, ENDOCRINOLOGY, V136, P5182, DOI 10.1210-en.136.11.5182; Dupre J, 1997, DIABETES CARE, V20, P381; DUPRE J, 1973, J CLIN ENDOCR METAB, V37, P826; DUPRE J, 1995, DIABETES, V44, P626, DOI 10.2337-diabetes.44.6.626; Egan JM, 2003, DIABETES-METAB RES, V19, P115, DOI 10.1002-dmrr.357; ELRICK H, 1964, J CLIN ENDOCR METAB, V24, P1076; ENG J, 1992, J BIOL CHEM, V267, P7402; Faradji RN, 2008, TRANSPLANTATION, V86, P1658, DOI 10.1097-TP.0b013e31818fe448; FEHMANN HC, 1992, ENDOCRINOLOGY, V130, P159, DOI 10.1210-en.130.1.159; Froud T, 2008, TRANSPLANTATION, V86, P36, DOI 10.1097-TP.0b013e31817c4ab3; Ghofaili Khalid Al, 2007, Transplantation, V83, P24, DOI 10.1097-01.tp.0000251379.46596.2d; Greenbaum CJ, 2002, DIABETES, V51, P951, DOI 10.2337-diabetes.51.4.951; GUTNIAK M, 1992, NEW ENGL J MED, V326, P1316, DOI 10.1056-NEJM199205143262003; Hadjiyanni I, 2008, ENDOCRINOLOGY, V149, P1338, DOI 10.1210-en.2007-1137; Holz GG, 2003, CURR MED CHEM, V10, P2471, DOI 10.2174-0929867033456648; Kielgast A, 2010, J CLIN ENDOCR METAB, V95, P2492; MADSBAD S, 1980, ACTA ENDOCRINOL-COP, V95, P359; Li YH, 2005, DIABETES, V54, P482; LICKLEY HLA, 1981, SURGERY, V90, P186; List JF, 2004, AM J PHYSIOL-ENDOC M, V286, pE875, DOI 10.1152-ajpendo.00007.2004; Liu MJ, 2010, J MOL MED-JMM, V88, P351, DOI 10.1007-s00109-009-0571-z; Loew ER, 1940, AM J PHYSIOL, V128, P0298; Loew ER, 1940, AM J PHYSIOL, V129, P0659; Loew ER, 1939, AM J PHYSIOL, V126, P270; Lopez-Delgado MI, 1998, ENDOCRINOLOGY, V139, P2811, DOI 10.1210-en.139.6.2811; Lugari R, 2000, HORM METAB RES, V32, P424, DOI 10.1055-s-2007-978665; MADSBAD S, 1983, DIABETOLOGIA, V24, P141; MATSUYAMA T, 1975, HORM METAB RES, V7, P452; MCINTYRE N, 1964, LANCET, V2, P20; Meier JJ, 2005, DIABETES-METAB RES, V21, P91, DOI 10.1002-dmrr.538; Meier JJ, 2001, DIABETES, V50, P2497, DOI 10.2337-diabetes.50.11.2497; Meier JJ, 2008, DIABETOLOGIA, V51, P703, DOI 10.1007-s00125-008-0936-9; Meneilly GS, 2003, DIABETES CARE, V26, P837, DOI 10.2337-diacare.26.3.837; MERIDA E, 1993, J CLIN ENDOCR METAB, V77, P1654, DOI 10.1210-jc.77.6.1654; MOJSOV S, 1987, J CLIN INVEST, V79, P616, DOI 10.1172-JCI112855; Morales M, 1997, DIABETES, V46, P1264, DOI 10.2337-diabetes.46.8.1264; NAUCK MA, 1993, J CLIN INVEST, V91, P301, DOI 10.1172-JCI116186; Ogawa N, 2004, DIABETES, V53, P1700, DOI 10.2337-diabetes.53.7.1700; Perez-Arana G, 2010, ENDOCRINOLOGY, V151, P2538, DOI 10.1210-en.2009-1113; Raman VS, 2010, DIABETES CARE, V33, P1294, DOI 10.2337-dc09-1959; Rocca AS, 2001, ENDOCRINOLOGY, V142, P1148, DOI 10.1210-en.142.3.1148; Roep BO, 2007, ANN NY ACAD SCI, V1103, P1, DOI 10.1196-annals.1394.018; SAKURAI H, 1975, DIABETOLOGIA, V11, P427, DOI 10.1007-BF00429911; Schirra J, 1998, J CLIN INVEST, V101, P1421, DOI 10.1172-JCI1349; SCHMIDT WE, 1985, DIABETOLOGIA, V28, P704, DOI 10.1007-BF00291980; Scrocchi LA, 1996, NAT MED, V2, P1254, DOI 10.1038-nm1196-1254; Serre V, 1998, ENDOCRINOLOGY, V139, P4448, DOI 10.1210-en.139.11.4448; Sherry NA, 2007, ENDOCRINOLOGY, V148, P5136, DOI 10.1210-en.2007-0358; Stoffers DA, 2000, DIABETES, V49, P741, DOI 10.2337-diabetes.49.5.741; Suarez-Pinzon WL, 2008, DIABETES, V57, P3281, DOI 10.2337-db08-0688; Suen PM, 2006, INT J BIOCHEM CELL B, V38, P951, DOI 10.1016-j.biocel.2005.08.005; Thomsen C, 2003, AM J CLIN NUTR, V77, P605; Varga Timea, 2010, Orvosi Hetilap, V151, P899, DOI 10.1556-OH.2010.28842; Vella A, 2002, DIABETOLOGIA, V45, P1410, DOI 10.1007-s00125-002-0924-4; Vella A, 2001, DIABETES, V50, P565, DOI 10.2337-diabetes.50.3.565; VILLANUEVAPENACARRILLO ML, 1994, DIABETOLOGIA, V37, P1163, DOI 10.1007-BF00418382; VILLANUEVAPENACARRILLO ML, 1995, J ENDOCRINOL, V146, P183, DOI 10.1677-joe.0.1460183; Vilsboll T, 2003, J CLIN ENDOCR METAB, V88, P2706, DOI 10.1210-jc.2002-021873; Wang YH, 1997, J CLIN INVEST, V99, P2883, DOI 10.1172-JCI119482; Yang ZD, 2006, BIOCHEM BIOPH RES CO, V344, P1017, DOI 10.1016-j.bbrc.2006.03.177; Zhang J, 2007, DIABETOLOGIA, V50, P1900, DOI 10.1007-s00125-007-0737-6
dc.description.citedCount 7
dc.description.citedTotWOSCount 7
dc.description.citedWOSCount 7
dc.format.extentCount 8
dc.identifier.articleNo
dc.identifier.coden CDRUA
dc.identifier.pubmedID 22767380
dc.identifier.scopusID 84870787581
dc.identifier.url
dc.publisher.address 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr Curr. Diabetes Rep.
dc.relation.ispartOfIssue 5
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle Current Diabetes Reports
dc.relation.ispartofPubTitleAbbr Curr. Diabetes Rep.
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 12
dc.source.ID WOS:000308286400014
dc.type.publication Journal
dc.subject.otherAuthKeyword GLP-1
dc.subject.otherAuthKeyword Glucagon
dc.subject.otherAuthKeyword Glycemic control
dc.subject.otherAuthKeyword Insulin
dc.subject.otherAuthKeyword Type 1 diabetesmellitus
dc.subject.otherChemCAS C peptide, 59112-80-0
dc.subject.otherChemCAS arginine, 1119-34-2, 15595-35-4, 7004-12-8, 74-79-3
dc.subject.otherChemCAS exendin 4, 141732-76-5, 141758-74-9
dc.subject.otherChemCAS gastrin, 9002-76-0
dc.subject.otherChemCAS glucagon, 11140-85-5, 62340-29-8, 9007-92-5
dc.subject.otherChemCAS glucagon like peptide 1, 89750-14-1
dc.subject.otherChemCAS glucose, 50-99-7, 84778-64-3
dc.subject.otherChemCAS insulin, 9004-10-8
dc.subject.otherChemCAS lisofylline, 100324-81-0, 151852-32-3, 6493-06-7
dc.subject.otherChemCAS Blood Glucose
dc.subject.otherChemCAS Glucagon-Like Peptide 1, 89750-14-1
dc.subject.otherChemCAS Hypoglycemic Agents
dc.subject.otherChemCAS Insulin
dc.subject.otherIndex arginine
dc.subject.otherIndex C peptide
dc.subject.otherIndex exendin 4
dc.subject.otherIndex gastrin
dc.subject.otherIndex glucagon
dc.subject.otherIndex glucagon like peptide 1
dc.subject.otherIndex glucagon like peptide 1 receptor agonist
dc.subject.otherIndex glucagon like peptide 2
dc.subject.otherIndex glucose
dc.subject.otherIndex insulin
dc.subject.otherIndex lisofylline
dc.subject.otherIndex lymphocyte antibody
dc.subject.otherIndex placebo
dc.subject.otherIndex apoptosis
dc.subject.otherIndex article
dc.subject.otherIndex cell proliferation
dc.subject.otherIndex continuous infusion
dc.subject.otherIndex dietary intake
dc.subject.otherIndex drug dose comparison
dc.subject.otherIndex drug efficacy
dc.subject.otherIndex drug mechanism
dc.subject.otherIndex glucose blood level
dc.subject.otherIndex glucose transport
dc.subject.otherIndex glycemic control
dc.subject.otherIndex human
dc.subject.otherIndex hyperglycemia
dc.subject.otherIndex insulin dependent diabetes mellitus
dc.subject.otherIndex insulin release
dc.subject.otherIndex insulin resistance
dc.subject.otherIndex Medline
dc.subject.otherIndex morning dosage
dc.subject.otherIndex non insulin dependent diabetes mellitus
dc.subject.otherIndex nonhuman
dc.subject.otherIndex pancreas islet beta cell
dc.subject.otherIndex pancreas islet cell function
dc.subject.otherIndex pathophysiology
dc.subject.otherIndex postprandial state
dc.subject.otherIndex protein function
dc.subject.otherIndex protein interaction
dc.subject.otherIndex randomized controlled trial (topic)
dc.subject.otherIndex signal transduction
dc.subject.otherIndex stomach emptying
dc.subject.otherIndex treatment duration
dc.subject.otherIndex Animals
dc.subject.otherIndex Blood Glucose
dc.subject.otherIndex Diabetes Mellitus, Type 1
dc.subject.otherIndex Glucagon-Like Peptide 1
dc.subject.otherIndex Humans
dc.subject.otherIndex Hypoglycemic Agents
dc.subject.otherIndex Insulin
dc.subject.otherKeywordPlus GLUCAGON-LIKE PEPTIDE-1
dc.subject.otherKeywordPlus GASTRIC-INHIBITORY POLYPEPTIDE
dc.subject.otherKeywordPlus NOD MICE
dc.subject.otherKeywordPlus BETA-CELLS
dc.subject.otherKeywordPlus 7-36 AMIDE
dc.subject.otherKeywordPlus GLYCEMIC EXCURSIONS
dc.subject.otherKeywordPlus PANCREATIC GLUCAGON
dc.subject.otherKeywordPlus INSULIN-SECRETION
dc.subject.otherKeywordPlus GLYCOGEN-SYNTHASE
dc.subject.otherKeywordPlus GLUCOSE-TOLERANCE
dc.subject.otherWOS Endocrinology and Metabolism


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account